이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

암 환자의 게놈 프로파일링

2026년 9월 23일 업데이트: Memorial Sloan Kettering Cancer Center

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

연구 개요

연구 유형

관찰

등록 (추정된)

200

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: David Solit, MD
  • 전화번호: 646-888-2641

연구 연락처 백업

  • 이름: Zsofia Stadler, MD
  • 전화번호: 646-888-4039

연구 장소

    • Connecticut
      • Bridgeport, Connecticut, 미국, 06606
        • 아직 모집하지 않음
        • St. Vincent (Data Collection Only)
        • 연락하다:
          • Christopher Iannuzzi, MD
          • 전화번호: 203-576-6000
      • Hartford, Connecticut, 미국, 06102
        • 아직 모집하지 않음
        • Hartford Healthcare Cancer Institute @ Hartford Hospital
        • 연락하다:
          • Andrew Salner, MD
          • 전화번호: 860-972-2803
      • Norwalk, Connecticut, 미국, 06850
        • 모병
        • Norwalk Hospital
        • 연락하다:
          • Linda Vahdat, MD
          • 전화번호: 203-845-4811
    • Florida
      • Miami, Florida, 미국, 33143
        • 모병
        • Baptist Alliance MCI
        • 연락하다:
          • John Diaz, MD
          • 전화번호: 786-596-2000
    • New Jersey
      • Basking Ridge, New Jersey, 미국, 07920
        • 모병
        • Memorial Sloan Kettering Basking Ridge
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
      • Middletown, New Jersey, 미국, 07748
        • 모병
        • Memorial Sloan Kettering Monmouth
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
      • Montvale, New Jersey, 미국, 07645
        • 모병
        • Memorial Sloan Kettering Bergen
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
    • New York
      • Brooklyn, New York, 미국, 11203
        • 모병
        • Kings County Hopsital Center
        • 연락하다:
          • Jason Gonsky, MD
          • 전화번호: 718-245-2847
      • Commack, New York, 미국, 11725
        • 모병
        • Memorial Sloan Kettering Cancer Commack
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
      • Harrison, New York, 미국, 10604
        • 모병
        • Memorial Sloan Kettering Westchester
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
      • Jamaica, New York, 미국, 11432
        • 모병
        • Queens Cancer Center of Queens Hospital
        • 연락하다:
          • Debra Ferman, MD
          • 전화번호: 718-579-6021
      • New York, New York, 미국, 10065
        • 모병
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
        • 연락하다:
          • Zsofia Stadler, MD
          • 전화번호: 646-888-4039
        • 수석 연구원:
          • David Solit, MD
      • New York, New York, 미국, 10029
        • 모병
        • Metropolitan Hospital Center
        • 연락하다:
          • Anitha Srinivasan, MD
          • 전화번호: 212-423-6262
      • New York, New York, 미국, 10035
        • 모병
        • Ralph Lauren Center for Cancer Care and Prevention
        • 연락하다:
          • Lewis P. Kampel, MD
          • 전화번호: 646-422-4474
      • Richmond Hill, New York, 미국, 11418
        • 모병
        • Medisys Health Network (Data Collection Only)
        • 연락하다:
          • Rosa Nouvini, MD
          • 전화번호: 718-206-6000
      • The Bronx, New York, 미국, 10451
        • 모병
        • NYC Health & Hospitals /Lincoln Medical Center
        • 연락하다:
          • Monica Reddy Muppidi, MD
          • 전화번호: 718-579-4977
        • 수석 연구원:
          • Monica Reddy Muppidi, MD
      • Uniondale, New York, 미국, 11553
        • 모병
        • Memorial Sloan Kettering Nassau
        • 연락하다:
          • David Solit, MD
          • 전화번호: 646-888-2641
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • 모병
        • Lehigh Valley Health Network
        • 연락하다:
          • Suresh Nair, MD
          • 전화번호: 610-402-7880

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients with solid or hematologic cancers who may be and considered potential candidates for a therapeutic protocol will be recruited to Part A of this study. Enrollment to therapeutic clinical trials will not be contingent on enrollment in this protocol.

Part B: Research Collection Cohort Patients potentially appropriate will be identified by their treating physician in each participating Disease Management Team.

설명

Inclusion Criteria:

Part A:

  • Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
  • Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
  • Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.

Part B:

  • Patients must be successfully registered to Part A of MSKCC IRB# 12-245
  • Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
  • Patient must have successfully consented to Part A of this study.

Part D:

  • Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion Criteria:

All Parts:

  • Unwilling or unable to provide informed consent.

Part C:

  • All patients consenting to Part A are eligible to consent to 12-245, Part C. Most patients will be eligible to receive clinical germline testing with return of results to the patient/health care providers. However, several exclusion criteria apply and are outlined below

    1. Solid tumor patients: Secondary germline analysis using BAM files generated for MSK-IMPACT testing is not an option for patients with solid tumors and an acute or chronic hematologic neoplasm that would preclude the use of blood or saliva as a source of germline DNA. Such patient may be eligible for primary germline testing using a non-blood source of germline DNA as per standard clinical guidelines. Solid tumor patients who have had an allogenic bone marrow/stem cell transplant will only be considered eligible for germline testing under Part C if a sample adequate for germline testing had previously been collected prior to allogenic bone marrow/stem cell transplant.
    2. Hematologic cancer patients: For patients with a hematopoietic neoplasm, germline testing may be an option under Part C using nail clippings or another non-blood source of DNA as per standard clinical practice. For patients who have had an allogenic bone marrow/stem cell transplant, clinical germline testing will only be considered under Part C if a sample adequate for germline testing had previously been collected prior to Allogenic bone marrow/stem cell transplant.

Part D

  • Exclusion criteria are same as those for Part C outlined above.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Pts with solid tumors

Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.

Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.

Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").

Part D: Germline Profiling for Individuals at Elevated Cancer Risk

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
frequency of "actionable" oncogenic mutations
기간: 1 year

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

1 year

2차 결과 측정

결과 측정
측정값 설명
기간
To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.
기간: 1 year

The Bioinformatics Core will assist in interpreting data generated by next-generation sequencing techniques such as WES and WGS.

1 year
interrogate the mechanisms
기간: 1 year

underlying response and resistance (de-novo and acquired) to targeted therapy. The research assay(s) used to accomplish this will vary based on the clinical setting and tissue available and may include Sanger, Sequenom, MiSeq, exon-capture (ie: IMPACT), whole exome, and whole genome sequencing.

1 year
To explore the genetic mechanisms of tumorigenesis
기간: 2

in a subset of specimens with no identifiable culpritic genomic alterations on highly-multiplexed next-generation sequencing (i.e.: IMPACT testing) by using even more comprehensive investigational profiling techniques such as whole exome sequencing, whole genome sequencing or RNA sequencing

2

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: David Solit, MD, Memorial Sloan Kettering Cancer Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2013년 1월 1일

기본 완료 (추정된)

2027년 1월 1일

연구 완료 (추정된)

2027년 1월 1일

연구 등록 날짜

최초 제출

2013년 1월 21일

QC 기준을 충족하는 최초 제출

2013년 1월 21일

처음 게시됨 (추정된)

2013년 1월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 24일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 23일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다